Format

Send to

Choose Destination
Cell Mol Life Sci. 2004 Dec;61(23):2924-31.

Kit as a human oncogenic tyrosine kinase.

Author information

1
Shionogi Pharmaceutical Company, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan. yukihiko.kitamura@shionogi.co.jp

Abstract

Signals through Kit receptor tyrosine kinase are essential for development of erythrocytes, melanocytes, germ cells, mast cells and interstitial cells of Cajal (ICCs). Mice and rats with a double gene dose of loss-of-function mutations of Kit show depletion of these cells. Although human homozygotes with loss-of-function mutations of Kit have not been reported, gain-of-function mutations of Kit result in development of tumors from mast cells, germ cells and ICCs in humans. The ICC tumors are called gastrointestinal stromal tumors (GISTs), and GISTs are a good target for the Kit inhibitor imatinib mesylate. The interrelationship between the type of Kit gain-of-function mutations and the therapeutic effect of imatinib mesylate has been well characterized in GISTs. Kit is interesting from both a biological and clinical view-point.

PMID:
15583854
DOI:
10.1007/s00018-004-4273-y
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center